David Topper serves as the Chief Financial Officer (CFO) at Arcutis Biotherapeutics Inc., a position he has held since joining the company in 2019. Arcutis Biotherapeutics is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with immune-mediated dermatological diseases and conditions. In his role as CFO, Topper is responsible for overseeing the financial operations and strategy of the company, ensuring its fiscal health and supporting its growth trajectory. Before joining Arcutis, Topper had a distinguished career in the life sciences industry, holding various senior financial positions at several notable companies. He previously served as the CFO at Tobira Therapeutics, where he played a pivotal role in guiding the company through its acquisition by Allergan in 2016. Prior to Tobira, Topper was the CFO at Hyperion Therapeutics, where he was instrumental in leading the company through its IPO and subsequent growth until its acquisition by Horizon Pharma in 2015. His extensive experience in financial management, strategic planning, and corporate development has been crucial in driving the success of the companies he has worked with. Topper's achievements in the biopharmaceutical sector are marked by his ability to navigate complex financial landscapes and drive value creation. At Arcutis, he has been integral in securing funding and managing the company's financial resources to support its clinical development programs and commercialization efforts. His strategic financial leadership continues to be a key asset for Arcutis as it works towards bringing new treatments to patients suffering from dermatological conditions.